That is because scientists keen to achieve more precise control over an organism’s genetics are experimenting with a ...

End-to-end pipelines and regulatory advances aim to expand gene editing to broad patient populations Ajay Gannerkote, ...

Scientists have corrected gene mutations in mice causing an ultra-rare disease by editing DNA directly in the brain with a single injection, a feat with profound implications for patients with ...

Biotech companies that use gene editing tools can face intellectual property (IP) challenges during commercialization. That’s the view of Austin Hallgren, strategic account manager for bioproduction ...

C&EN’s award-winning podcast Inflection Point leans on our 100-year archive to trace headline topics in science today back to their disparate and surprising roots. In each episode, we explore three ...

Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion, the drugmaker’s latest investment in an experimental medicine that could fuel its long-term growth.

Crispr Therapeutics (CRSP) is downgraded to "Hold" as current valuation already reflects optimism for CTX310 Phase I results and pipeline progress. Intellia Therapeutics (NTLA) maintains a "Buy" ...

In this article, we will be taking a look at the 8 gene-editing stocks to buy. Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA ...

This guidance emphasises the potential of NGS methods in mitigating safety risks associated with therapies incorporating ...